Camino HIV Prevention and Care Study

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study targets Latin American adults in Washington, DC and the San Francisco Bay Area who have unmet HIV prevention and care needs. It uses a status-neutral, multi-level approach that integrates legal services with peer navigation to reduce barriers and fear of healthcare. A quasi-experimental wait-list design compares outcomes for those receiving the Camino intervention with those on a rolling waitlist over 18 months, focusing on HIV testing, PrEP uptake, and HIV care metrics such as appointment attendance, ART adherence, and viral load for people living with HIV. Secondary aims explore how legal, social, and mental health factors relate to HIV prevention and care engagement. The study enrolls 50 participants and partners with Oasis Legal Services and La Clínica del Pueblo, with lead sponsor American University and collaboration from NIMH.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Assigned male sex at birth
* Identifies as a Latin American man who has sex with men, transgender woman, or nonbinary person on the feminine spectrum
* Not a U.S. citizen
* Speaks Spanish or English
* Resides in the Washington, DC metropolitan area or San Francisco Bay Area
* Willing to receive health and/or supportive services through participating study partners
* Willing to allow the study to obtain relevant medical record information
* Meets one of the following HIV prevention or care criteria:
* Living with HIV and either not linked to HIV care, has missed an HIV care appointment within the past year, is not taking antiretroviral therapy (ART), or has a detectable viral load; or Not living with HIV, is sexually active, and is either not taking pre-exposure prophylaxis (PrEP) or has not received an HIV test within the past 6 months

Exclusion Criteria:

* Younger than 18 years
* Does not meet the inclusion criteria above

Where it's running

• La Clínica del Pueblo
  Washington D.C., District of Columbia, United States Recruiting
• Oasis Legal Services
  Berkeley, California, United States Not yet recruiting

Study contacts

• Principal investigator: Thespina J Yamanis, Ph.D., MPH — American University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

• Mass Balance and Oral Bioavailability of a radiolabeled HIV drug

  This early-phase study tests how the radiolabeled VH4524184 is absorbed, distributed, metabolized, and excreted in adults with HIV.

  Recruiting Phase 1 ViiV Healthcare · Groningen · NCT07636928

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.